Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Topical antibiotic (mRNA synthetase inhibitor)

Mupirocin 2% (Nasal / Wound)

Brand names: Bactroban

Mupirocin 2% is a topical antibacterial used for nasal decolonisation of Staphylococcus aureus (including MRSA) and for localised skin and wound infection; the nasal ointment and skin preparation are distinct formulations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It reversibly inhibits bacterial isoleucyl-tRNA synthetase, halting protein synthesis and giving activity chiefly against staphylococci and streptococci.

Prescribing in practice

  • Reserve mupirocin for targeted use such as MRSA decolonisation and limited courses, because prolonged or widespread use drives resistance; it is not for routine prophylaxis over large burns.
  • Use the correct product for the site — the nasal preparation for the anterior nares and the cutaneous preparation for skin and wounds — and avoid contact with the eyes.
  • The polyethylene glycol skin base can be absorbed and is a concern when applied to extensive open wounds in patients with renal impairment.

Monitoring

Monitor the treated site for resolution and local irritation, and where used for decolonisation follow local screening protocols to confirm clearance.

Counselling the patient

  • Use this only at the site and for the duration advised to avoid resistance.
  • Use the nasal product inside the nose and the skin product on the skin as directed.
  • Report any rash or irritation where it is applied.

Evidence & guidelines

Mupirocin nasal decolonisation is supported by infection-prevention guidance for staphylococcal carriage and MRSA control.

Reference: NICE NG118 MRSA; PHE MRSA Decolonisation Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways